Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- Home

Sleep apnoea

9 findings across 6 drug records. Domain pages are descriptive indexes, not advice.

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Most represented records

Tirzepatide (3)

GLP-1-based therapies, multi-agent (2)

Liraglutide (1)

Multi-agent review synthesis (1)

Retatrutide (1)

Semaglutide (1)

Evidence spread

High evidence 5 Moderate evidence 0 Low evidence 3 Very low evidence 1

Multi-agent review synthesis STATUS UNKNOWN
Sleep apnoea Not directional
Low evidence

INDICATION LANDSCAPE / REGULATORY CONTEXT: OSA is now a validated incretin indication path - tirzepatide became the first-ever drug approved for OSA (FDA, Dec 2024) on...

Giblin K et al. Design of the TRIUMPH phase-3 retatrutide programme. Diabetes Obes Metab ... Source
Full findingINDICATION LANDSCAPE / REGULATORY CONTEXT: OSA is now a validated incretin indication path - tirzepatide became the first-ever drug approved for OSA (FDA, Dec 2024) on the SURMOUNT-OSA AHI evidence, and Lilly IS pursuing retatrutide along the same path (TRIUMPH OSA cohorts with AHI as a primary endpoint, named as a registrational complication in the TRIUMPH design paper). Reta's place in the path is signalled-and-registered but as-yet-unproven (no OSA results, no indication).
PopulationClass/regulatory context. Tirzepatide anchor: SURMOUNT-OSA (N=469, 52 wk). Reta pipeline: TRIUMPH-1 (NCT05929066) / TRIUMPH-2 (NCT05929079) OSA subsets (AHI >=15 on PSG).
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorsplacebo
GLP-1-based therapies, multi-agent STATUS UNKNOWN
Sleep apnoea Not directional
Low evidence

MECHANISM (the central question): incretin OSA benefit is WEIGHT-DOMINANT - AHI reduction tracks weight loss across SCALE and SURMOUNT-OSA, and the canonical mediator...

Wang SH, Keenan BT, Wiemken A, ... Schwab RJ. Effect of Weight Loss on Upper Airway Anato... Source
Full findingMECHANISM (the central question): incretin OSA benefit is WEIGHT-DOMINANT - AHI reduction tracks weight loss across SCALE and SURMOUNT-OSA, and the canonical mediator is reduction in upper-airway / parapharyngeal and especially TONGUE fat. A weight-INDEPENDENT/direct component (residual upper-airway-fat pathway, plus possible rostral fluid shift, lung-volume and ventilatory-control/loop-gain effects) is PLAUSIBLE but NOT PROVEN for incretins: no incretin OSA trial has isolated a weight-independent drug effect. Both poles stand.
PopulationMechanistic synthesis. Key imaging substrate: 67 adults with obesity + OSA, upper-airway + abdominal MRI and sleep study before/after weight loss (lifestyle or bariatric).
Fundingnot-stated
GLP-1-based therapies, multi-agent STATUS UNKNOWN
Sleep apnoea Not directional
High evidence

SURROGATE-vs-HARD-OUTCOME caveat: AHI is the registrational endpoint for incretin OSA trials, but lowering OSA severity does NOT guarantee hard-outcome benefit. The...

McEvoy RD et al. CPAP for Prevention of Cardiovascular Events in OSA (SAVE). N Engl J Med... Source
Full findingSURROGATE-vs-HARD-OUTCOME caveat: AHI is the registrational endpoint for incretin OSA trials, but lowering OSA severity does NOT guarantee hard-outcome benefit. The CPAP randomised precedent shows AHI/severity can be reduced without reducing major CV events - SAVE and ISAACC were both NULL for CV outcomes despite effective apnoea-severity reduction. The same caveat applies to drug-induced AHI reduction: the incretin OSA RCTs (SCALE, SURMOUNT-OSA) demonstrate AHI reduction (a surrogate), not reduced CV events, mortality or hard OSA outcomes. BOTH POLES (kept explicit): the CPAP precedent is WEAKENED by low device adherence (~3-4 hr/night) and selection of low-sleepiness populations, so it does not prove drug-induced AHI reduction is futile; but the narrow claim stands - AHI reduction alone is not established proof of hard-outcome benefit.
PopulationCross-cutting surrogate note. SAVE (N=2717, CV-disease population) and ISAACC (N=1264, post-ACS); both tested CPAP (not an incretin) and were academically led.
Fundingmixed-NHMRC (Australia) and Philips Respironics/device industry
Comparatorsusual care; sham/no CPAP
Liraglutide MARKETED
Sleep apnoea Decrease
High evidence

SCALE Sleep Apnea was the historical GLP-1 mono-agonist OSA RCT and proof-of-concept that an incretin lowers AHI: liraglutide 3.0 mg, adjunct to diet/exercise, reduced...

Blackman A, Foster GD, Zammit G et al. Effect of liraglutide 3.0 mg in individuals with o... Source
Full findingSCALE Sleep Apnea was the historical GLP-1 mono-agonist OSA RCT and proof-of-concept that an incretin lowers AHI: liraglutide 3.0 mg, adjunct to diet/exercise, reduced AHI more than placebo at 32 weeks in obese non-diabetic adults with moderate-to-severe OSA unwilling/unable to use CPAP. The effect is modest and parallels modest (~4% placebo-subtracted) weight loss.
PopulationSCALE Sleep Apnea (NCT01557166); N=359 (liraglutide 180, placebo 179); obese (mean BMI 39.1) non-diabetic, baseline mean AHI 49.2 events/hr, 67% severe; CPAP-refusing; 32-wk double-blind RCT, both arms on a 500 kcal/day deficit + exercise.
Fundingindustry - Novo Nordisk
Comparatorsplacebo
Retatrutide INVESTIGATIONAL
Sleep apnoea Not directional
Very low evidence

RETATRUTIDE-DIRECT OSA POSITION: reta has no published OSA/AHI outcome data. Its OSA relevance rests on (a) the registrational TRIUMPH OSA endpoints (results pending)...

Position derived from TRIUMPH design (Giblin K et al., Diabetes Obes Metab 2025, PMID 410...
Full findingRETATRUTIDE-DIRECT OSA POSITION: reta has no published OSA/AHI outcome data. Its OSA relevance rests on (a) the registrational TRIUMPH OSA endpoints (results pending) and (b) the inference that, because OSA benefit in this class appears largely weight-mediated, the agent with the largest weight loss should deliver the largest AHI reduction. Stated as an EXPECTATION conditional on weight-mediation - not an outcome reta has demonstrated.
Populationn/a (positional/inferential row). Weight-loss anchor: reta phase-2 (Jastreboff 2023, obesity, 48 wk) up to ~24% mean weight loss (weight-loss domain).
Fundingindustry - Eli Lilly (trial sponsor; inferred from registration trial)
Semaglutide MARKETED
Sleep apnoea Not directional
Low evidence

EVIDENCE GAP: as of this sweep there is NO dedicated semaglutide randomised OSA trial with a polysomnographic AHI primary endpoint - a notable hole given semaglutide...

Kutler RB et al. GLP-1 RA Utilization Among Sleep Surgery Clinic Patients. Otolaryngol He... Source
Full findingEVIDENCE GAP: as of this sweep there is NO dedicated semaglutide randomised OSA trial with a polysomnographic AHI primary endpoint - a notable hole given semaglutide is the dominant GLP-1. OSA benefit for semaglutide is inferred from its weight loss (STEP/SELECT, neither using a sleep-apnoea endpoint) on the unproven weight-mediation assumption; available OSA-context data are observational/utilisation.
Populationn/a - gap statement. Supporting observational source: GLP-1 RA utilisation among sleep-surgery clinic patients (retrospective, n=384, single tertiary centre).
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Tirzepatide MARKETED
Sleep apnoea Not directional
High evidence

The FDA approved tirzepatide (Zepbound) in December 2024 for moderate-to-severe obstructive sleep apnoea in adults with obesity - the first-ever drug indication for...

US FDA. FDA approves first medication for obstructive sleep apnea (Zepbound / tirzepatide... Source
Full findingThe FDA approved tirzepatide (Zepbound) in December 2024 for moderate-to-severe obstructive sleep apnoea in adults with obesity - the first-ever drug indication for OSA, establishing AHI reduction as an approvable registrational endpoint for this class.
PopulationRegulatory label population: adults with moderate-to-severe OSA and obesity (BMI >=30), adjunct to diet/exercise. Approval 20 Dec 2024.
Fundingregulatory agency (FDA/EMA/MHRA/WHO)
Tirzepatide MARKETED
Sleep apnoea Decrease
High evidence

In SURMOUNT-OSA trial 1 (APNEA-1, participants NOT on positive airway pressure), tirzepatide at max-tolerated dose (10/15 mg) markedly reduced the apnoea-hypopnoea...

Malhotra A, Grunstein RR, Fietze I et al; SURMOUNT-OSA Investigators. Tirzepatide for the... Source
Full findingIn SURMOUNT-OSA trial 1 (APNEA-1, participants NOT on positive airway pressure), tirzepatide at max-tolerated dose (10/15 mg) markedly reduced the apnoea-hypopnoea index vs placebo over 52 weeks in adults with moderate-to-severe OSA and obesity.
PopulationSURMOUNT-OSA trial 1 (NCT05412004), phase-3 double-blind RCT; PAP-naive; moderate-to-severe OSA (baseline mean AHI 51.5 events/hr), obesity (mean BMI 39.1); tirzepatide 10/15 mg MTD vs placebo, 52 wk. Combined SURMOUNT-OSA N=469 across both trials.
Fundingindustry-Eli Lilly
Comparatorsplacebo
Tirzepatide MARKETED
Sleep apnoea Decrease
High evidence

In SURMOUNT-OSA trial 2 (APNEA-2, participants ON positive airway pressure), tirzepatide at max-tolerated dose (10/15 mg) markedly reduced the AHI vs placebo over 52...

Malhotra A, Grunstein RR, Fietze I et al; SURMOUNT-OSA Investigators. Tirzepatide for the... Source
Full findingIn SURMOUNT-OSA trial 2 (APNEA-2, participants ON positive airway pressure), tirzepatide at max-tolerated dose (10/15 mg) markedly reduced the AHI vs placebo over 52 weeks in adults with moderate-to-severe OSA and obesity.
PopulationSURMOUNT-OSA trial 2 (NCT05412004), phase-3 double-blind RCT; PAP-treated; moderate-to-severe OSA (baseline mean AHI 49.5 events/hr), obesity (mean BMI 38.7); tirzepatide 10/15 mg MTD vs placebo, 52 wk.
Fundingindustry-Eli Lilly
Comparatorsplacebo